Laura Poliseno

Laura Poliseno

Institute of Clinical Physiology, National Research Council (IFC-CNR)

Affiliated withNational Research Council (IFC-CNR)Core Research Laboratory, ISPRO

Research Area

Biography

In 2000, I graduated in Biological Sciences and in 2004 I got my PhD in Molecular Biotechnology, both at University of Pisa, Italy. In 2006, I moved to the US, where I became a post-doctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, first at MSKCC in New York and then at BIDMC-HMS in Boston. In 2009, I started a second post-doc in the lab of Prof. Iman Osman at NYU. In 2012, I was appointed as Principal Investigator of the Oncogenomics Unit of ITT (now ISPRO) and in 2016 I became Staff Scientist at the Institute of Clinical Physiology of the National Research Council in Pisa, Italy, where my lab is located.

Throughout my scientific career, my research interests have mostly revolved around non-coding RNAs (microRNAs, pseudogenes, ceRNAs) in cancer. Currently, the activities of my lab are focused on the study of the coding and non-coding regulatory networks that revolve around BRAFV600E isoforms in melanoma. To this end, we use a wide range of techniques, both in vitro (yeast, melanoma cell lines) and in vivo (melanoma modeling in zebrafish and in the mouse). We are also developing strategies for the selective delivery of drug combinations inside cancer cells.

JoVE Journal Publications

ArticleTotal : 1
Year
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Publication title

Cited by 2

2021

Other Publications

Article
Year
Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.

Oncogene| PubMed ID: 30664692

2019
2019
PTENP1 is a ceRNA for PTEN: it's CRISPR clear.

Journal of hematology & oncology| PubMed ID: 32517731

2020
2020
In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System.

Methods in molecular biology (Clifton, N.J.)| PubMed ID: 34160809

2021
CRISPR/Cas Technologies Applied to Pseudogenes.

Methods in molecular biology (Clifton, N.J.)| PubMed ID: 34165721

2021